PRESS RELEASE

innate pharma

INNATE PHARMA ANNOUNCES DATA PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

- ***Updated long term follow-up data and new data from cohort expansion in the Phase I of IPH4102 in advanced CTCL at the EORTC CLTF 2018 Meeting***
- ***Updated data from Phase I/II fully-enrolled study of monalizumab in combination with cetuximab in SCCHN at the ESMO 2018 congress***

Marseille, France, September 10, 2018, 07:00 AM CEST

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) today announced that updated data from ongoing clinical trials evaluating first-in-class antibody, IPH4102, and lead asset, monalizumab, partnered with AstraZeneca/MedImmune, will be presented at the EORTC CLTF* 2018 Meeting in St Gallen, Switzerland, September 27-29, 2018 and at the ESMO† 2018 Congress in Munich, Germany, October 19-23, 2018, respectively. Moreover, Eric Vivier, Chief Scientific Officer, is invited to the ESMO Congress as speaker in the *Early detection of cancer using minimally invasive biomarkers* Special Symposium.

EORTC CLTF 2018 for IPH4102:

- Title: IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
- Date and time: September 29, 2018, 8:30 – 9:45
- Presentation number: 078
- Session: Oral presentation, Session 8 / Treatment and clinical cases
- Presenter: Martine Bagot, Principal Investigator and Head of the Dermatology Department at the Saint-Louis Hospital, Paris, France
- Location: Olma Messen Hall 9.2, St-Gallen, Switzerland

ESMO 2018 Congress for monalizumab:

- Title: Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
- Date and time: October 20, 2018, 15:00
- Presentation number: 1049PD
- Session: Poster Discussion session – Head and neck
- Presenter: Jérôme Fayette, Medical Oncologist at the Centre Léon Bérard Lyon, France
- Location: Hall B3 – Room 23, ICM München, Munich, Germany

* European Organisation for Research and Treatment of Cancer and Cutaneous Lymphoma Task Force
† European Society for Medical Oncology

- Title: Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with Durvalumab plus Monalizumab (anti-NKG2A)
- Date & time: October 20, 2018, 12:30
- Presentation number: 1194P
- Session: Poster Display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research (ID 259)
- Presenter: Jennifer R. Diamond, Associate Professor, Division of Medical Oncology at the Colorado University, Denver, US
- Location: Hall A3, Poster Area Networking Hub, ICM München, Munich, Germany

- Title: Changes in the innate immune system as early events in cancer
- Date & time: October 22, 2018, 15:05 – 15:25
- Session: Special Symposium Early detection of cancer using minimally invasive biomarkers
- Presenter: Eric Vivier, Chief Scientific Officer of Innate Pharma, Marseille, France
- Location: Hall A1 – Room 17, ICM München, Munich, Germany

The full list of events Innate Pharma is participating in is available and regularly updated on the Company's website in the "Events" section.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the body's own immune system.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells.

The Company's broad pipeline includes several first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company.

Based in Marseille, France, Innate Pharma has more than 180 employees and is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com

PRESS RELEASE

innate pharma

Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH
LEI	9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

Innate Pharma

Markus Metzger / Danielle Spangler / Jérôme Marino

Tel.: +33 (0)4 30 30 30 30

investors@innate-pharma.com

International Media

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson

Tel.: +44 (0)20 3709 5700

InnatePharma@consilium-comms.com

French Media

ATCG Press

Marie Puvieux

Mob: +33 (0)6 10 54 36 72

presse@atcg-partners.com